Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose combination of **gamma-aminobutyric acid (GABA)**, a major inhibitory neurotransmitter in the central nervous system, and **tramadol**, a centrally acting synthetic opioid analgesic with serotonin-norepinephrine reuptake inhibition activity. This combination is formulated to provide enhanced pain relief; tramadol modulates pain via μ-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake, while gamma-aminobutyric acid may exert central inhibitory actions, though its pharmacological efficacy as a supplement is limited by blood-brain barrier permeability. The combo is usually indicated for moderate to severe pain where both neuropathic and nociceptive components are present, intending to produce synergistic analgesia through complementary action on multiple pain pathways[5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gamma-aminobutyric acid + tramadol.